Sapient Unveils Advanced Tumor Protein Mapping Platform to Decode Functional Biology Across Key Dimensions in Human Cancers
Sapient, an emerging leader in multi-omics data generation and biomarker discovery, has unveiled a major advancement in translational oncology research with the launch of its Tumor Protein Mapping Platform. This newly introduced platform represents a comprehensive suite of mass spectrometry-based discovery proteomics workflows designed to decode functional tumor biology directly from human tissue. By enabling high-resolution, protein-level insights across multiple biological dimensions, Sapient aims to address one of the most persistent challenges in oncology drug development: understanding what truly drives therapeutic response and resistance in human tumors.
At its core, the Tumor Protein Mapping Platform is built to interrogate four critical and interconnected dimensions of tumor biology. These include the druggable tumor cell surface proteome, phosphorylation-mediated signaling pathways, the tumor immune microenvironment, and mechanisms of therapeutic resistance. Together, these biological axes shape how tumors grow, evade treatment, and ultimately respond—or fail to respond—to therapy.
To operationalize this vision, Sapient has introduced four specialized workflows within the platform: SurfaceSeek™, SignalingSeek™, ImmuneSeek™, and ResistanceSeek™. Each workflow has been purpose-built to deliver deep, functionally relevant proteomic insights and has been optimized for compatibility with both fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tumor samples. This dual compatibility is particularly significant, as FFPE samples represent the vast majority of archived clinical tumor specimens worldwide, yet have historically been challenging to analyze at the proteomic level.
Among the four workflows, SurfaceSeek™ serves as the foundational component of the platform. It is specifically designed to directly measure proteins that are actively expressed on the surface of tumor cells—an area of immense interest for therapeutic targeting. Many modern cancer therapies, including antibody-drug conjugates (ADCs), T-cell engagers, and radioligand therapies, rely on the presence of accessible and tumor-specific surface proteins. However, traditional genomic and transcriptomic approaches often fall short in accurately predicting whether these targets are present, functional, and accessible on the tumor cell surface.
SurfaceSeek addresses this gap by combining Sapient’s advanced mass spectrometry-based discovery proteomics with a targeted enrichment strategy for mature N-linked glycoproteins. This selective enrichment is critical because it prioritizes proteins that have completed intracellular processing and trafficking, ensuring that the detected proteins are genuinely presented on the extracellular surface of tumor cells. As a result, researchers can directly assess not only the presence of a target but also its accessibility, density, and tumor selectivity.
Furthermore, SurfaceSeek provides peptide-level resolution, enabling the identification of specific protein isoforms and post-translationally modified proteoforms. This level of granularity is essential for drug development, as subtle differences in protein structure can significantly influence therapeutic binding and efficacy. By delivering such precise and functionally relevant data, SurfaceSeek empowers biopharma teams to make more informed decisions when selecting and validating therapeutic targets.
Complementing SurfaceSeek are three additional workflows that expand the platform’s ability to map tumor biology in a multidimensional manner. SignalingSeek™ focuses on the dynamic signaling networks that drive tumor growth and adaptation. By measuring phosphorylation events across key oncogenic pathways, this workflow provides direct insight into pathway activation states. It enables researchers to evaluate whether a therapeutic agent is effectively modulating its intended target pathway, while also revealing compensatory signaling mechanisms that may contribute to drug resistance.
ImmuneSeek™, another integral component of the platform, is dedicated to profiling the tumor immune microenvironment. It measures the presence and functional activity of immune cells within the tumor, as well as the signaling pathways that regulate immune response, suppression, and evasion. This information is particularly valuable in the era of immuno-oncology, where understanding the interplay between tumors and the immune system is critical for predicting response to therapies such as immune checkpoint inhibitors and cell-based treatments.
The fourth workflow, ResistanceSeek™, addresses one of the most complex and consequential aspects of cancer biology: therapeutic resistance. Tumors often adapt to treatment through coordinated changes in protein networks, enabling them to survive and proliferate despite therapeutic pressure. ResistanceSeek is designed to identify these adaptive protein networks across different treatment modalities, providing insights into how resistance emerges and how it might be overcome.
According to Jeramie Watrous, PhD, Co-Founder and Head of Analytical Research and Development at Sapient, the development of the Tumor Protein Mapping Platform builds upon the company’s next-generation FFPE proteomics capabilities. He emphasized that one of the platform’s key innovations lies in its ability to deliver highly consistent and reproducible results across both fresh-frozen and FFPE samples.
“Building upon our next-generation FFPE Proteomics offering, we have developed specialized workflows that enable precise, multi-dimensional characterization of tumor biology at the protein level—directly in human tumor tissue,” Watrous explained. “The key technical innovation is that these workflows perform with exceptional concordance across sample types, including SurfaceSeek’s selective glycoprotein enrichment and SignalingSeek’s deep phosphoproteomics. This allows us to unlock new biological insights from archived tissue samples that were previously inaccessible.”
This capability to analyze archived FFPE samples opens up vast opportunities for retrospective studies. Biopharma companies can now revisit existing biorepositories, extracting new layers of biological insight from samples that were originally collected for other purposes. This not only accelerates research timelines but also maximizes the value of previously collected clinical data.
Mo Jain, MD, PhD, Founder and Chief Scientific Officer at Sapient, highlighted the importance of adopting a multidimensional approach to understanding tumor biology. He noted that tumors are inherently complex systems, shaped by the interaction of multiple biological processes rather than a single defining feature.
“Tumors are not defined by a single biological dimension,” Jain said. “They are dynamic and complex systems where surface target accessibility, signaling pathway activation, immune function, and resistance mechanisms all interact to determine therapeutic outcome. By mapping each of these dimensions directly at the protein level, we provide drug development teams with a comprehensive and unified view of what is actually driving drug response—moving beyond genomic inference to capture the functional reality of human tumor biology.”
This shift from inference-based approaches to direct measurement represents a significant evolution in oncology research. While genomic data has long served as the foundation for target discovery and patient stratification, it does not always reflect the functional state of proteins, which are the primary effectors of cellular behavior. By focusing on proteomics, Sapient’s platform provides a more accurate and actionable understanding of tumor biology.
Jonathan Usuka, PhD, MBA, Chief Executive Officer at Sapient, emphasized that the platform was developed in response to ongoing discussions with oncology leaders facing critical decision-making challenges in drug development. He noted that many of these decisions—such as selecting therapeutic targets or advancing clinical candidates—are often made without direct evidence of the underlying biological mechanisms.
“This platform was shaped by conversations with oncology leaders who consistently expressed the need for direct measurement of the biological factors that determine therapeutic success,” Usuka said. “We designed these workflows to interrogate the key dimensions of tumor biology that influence drug outcomes, enabling our clients to make high-stakes decisions based on evidence rather than inference.”
The Tumor Protein Mapping Platform is now available to biopharma sponsors as a flexible solution. Each workflow can be deployed as a standalone service or integrated with others to provide a comprehensive, multi-dimensional profile of tumor biology. This modular approach allows researchers to tailor analyses to their specific needs, whether they are focused on target discovery, mechanism-of-action studies, or resistance characterization.
In addition, the platform can be supported by Sapient’s DynamiQ™ Tumor-Tissue virtual biobank, which offers streamlined access to well-annotated FFPE tumor samples. This resource further enhances the platform’s utility by providing researchers with high-quality biological material for analysis, reducing logistical barriers and accelerating project timelines.
In summary, the launch of Sapient’s Tumor Protein Mapping Platform marks a significant advancement in the field of oncology research and drug development. By integrating cutting-edge proteomics technologies with a multidimensional analytical framework, the platform provides unprecedented insight into the functional biology of human tumors. As the biopharmaceutical industry continues to seek more precise and effective therapies, tools that enable direct measurement of tumor biology—rather than reliance on indirect inference—are likely to play an increasingly central role in shaping the future of cancer treatment.
About Sapient
Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development.
Utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks, Sapient enables comprehensive biomarker-phenotype mapping across thousands of biosamples for discovery of robust protein, metabolite, and lipid biomarkers, drug targets, and clinical signatures of drug response. The company’s DynamiQ™ Insights Engine – a longitudinal molecular-clinical database collected from tens of thousands of human samples – enables rapid drug target identification, biomarker discovery and validation, and translational and clinical insights across all stages of drug development.
Source Link:https://www.businesswire.com/
